Summary
Cencora, Inc. (COR) has filed an 8-K to revise the presentation of its financial information within its previously filed 2025 Form 10-K. This revision is a result of a strategic review that led to a reorganization of its reporting structure, effective from the first quarter of fiscal year 2026. The company has moved to a new reporting structure consisting of three components: U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The U.S. Healthcare Solutions segment now includes U.S. Human Health (excluding legacy U.S. Consulting Services), while International Healthcare Solutions encompasses Alliance Healthcare, Innomar, World Courier, and specific components of Pharmalex. The 'Other' category, not considered a reportable segment, includes businesses for which strategic alternatives are being explored, such as MWI Animal Health, Profarma, U.S. Consulting Services, and remaining Pharmalex components. This filing updates specific sections of the 2025 Form 10-K to reflect this new segment alignment, though it does not amend or restate the audited consolidated financial statements themselves.
Key Highlights
- 1Cencora has revised its segment reporting structure within its 2025 Form 10-K to reflect a strategic reorganization.
- 2The new reporting structure comprises three key areas: U.S. Healthcare Solutions, International Healthcare Solutions, and Other.
- 3U.S. Healthcare Solutions now includes U.S. Human Health, excluding legacy consulting services.
- 4International Healthcare Solutions includes Alliance Healthcare, Innomar, World Courier, and strategic parts of Pharmalex.
- 5The 'Other' segment, which is not reportable, contains businesses under strategic review, including MWI Animal Health and Profarma.
- 6This 8-K filing updates previously reported segment results in the 2025 Form 10-K for clarity and consistency with the new structure.
- 7The revised financial information is presented to ensure consistency in documents that incorporate the 2025 Form 10-K by reference.